[Application Value of Neoadjuvant Targeted Therapy in Patients with EGFR-mutant Resectable Lung Adenocarcinoma].
The application of neoadjuvant targeted therapy in patients with EGFR-mutant resectable lung adenocarcinoma is safe and feasible, and is expected to become a highly promising neoadjuvant treatment option for the patients with EGFR-mutant lung adenocarcinoma.
Authors
- Tianbao Yang (ORCID: https://orcid.org/0000-0002-0557-843X)
- Ke‐Neng Chen (ORCID: https://orcid.org/0000-0002-4353-0568)
- Mingqiang Kang (ORCID: https://orcid.org/0000-0002-0715-6556)
- Kaiming Peng
- Shijie Huang (ORCID: https://orcid.org/0000-0002-9508-0458)
- Wu Wang (ORCID: https://orcid.org/0000-0003-0159-558X)
- Boyang Chen (ORCID: https://orcid.org/0000-0003-4857-1948)
- Mengying Fan (ORCID: https://orcid.org/0009-0008-8496-4312)
- Jinbiao Xie (ORCID: https://orcid.org/0000-0002-4021-9504)
- Wanpu Yan
Institutions
- Fujian Medical University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Ministry of Education (ET)
- Union Hospital (CN)
- Putian University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-07-20
- DOI
- https://doi.org/10.3779/j.issn.1009-3419.2025.106.18
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00